查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017518

骨關節炎鎮痛藥市場：2026年至2032年全球市場預測（按產品類型、給藥途徑、患者年齡層、疾病嚴重程度、最終用戶和分銷管道分類）

Osteoarthritis Pain Drug Market by Product Type, Route Of Administration, Patient Age Group, Disease Severity, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年，骨關節炎鎮痛藥市值為94.5億美元，預計2026年將成長至103.1億美元，複合年成長率為9.62%，到2032年將達到179.9億美元。

主要市場統計數據
基準年 2025 94.5億美元
預計年份：2026年 103.1億美元
預測年份 2032 179.9億美元
複合年成長率 (%) 9.62%

對不斷發展的骨關節炎鎮痛市場進行策略概述，提出臨床挑戰、患者多樣性以及相關人員的實用創新途徑。

由於患者需求各異、慢性疼痛病程複雜，以及不同年齡層和疾病嚴重程度的患者功能受損程度存在差異，骨關節炎仍是一個複雜的臨床挑戰。臨床醫生和保險公司越來越傾向於尋求能夠在快速緩解症狀、長期用藥安全性以及對運動功能和生活品質產生顯著改善之間取得平衡的治療方法。近期的臨床創新主要集中於改善現有藥物類別，並探索新的機制，以解決持續疼痛管理和疾病進展方面尚未解決的難題。

科學、臨床和商業性的變革正在重塑骨關節炎疼痛管理的整體情況，重新定義治療方案、劑量形式和對證據的期望。

在科學進步、支付方期望變化以及技術驅動的醫療模式的推動下，骨關節炎藥物市場正經歷著一場變革。生物製藥和標靶小分子化合物正在重新定義治療的可能性，而藥物科學也持續提供能夠提高耐受性和依從性的治療方案。同時，數位健康平台和遠端監測的出現使得對疼痛進展和功能改善的評估更加精準，從而支持了基於療效的醫保合約和個人化治療流程。

分析研究到 2025 年的定價政策趨勢如何重塑骨關節炎藥物的供應鏈、製造地和採購重點。

到2025年，累積貿易措施和關稅政策調整將對骨關節炎治療藥物的供應鏈、生產經濟和籌資策略產生多方面的影響。關鍵中間體和成品進口關稅的提高，加劇了依賴跨國分銷活性原料藥（API）和輔料的企業的投入成本波動。因此，製造商和合約研發生產機構（CDMO）正在加快供應商多元化，擴大本地灌裝和包裝能力，並重新審視長期採購契約，以降低關稅帶來的成本增加風險。

實用的細分見解揭示了產品類型、給藥途徑、分銷管道趨勢和患者人口統計特徵如何系統地決定臨床定位和商業策略。

基於細分的骨關節炎治療生態系統分析揭示了清晰的臨床和商業性特徵，這些特徵指南跨治療領域和給藥途徑的產品策略。就產品類型而言，皮質類固醇仍主要用於控制急性發作，而Cyclooxygenase-2抑制劑和非類固醇消炎劑在全身症狀控制中繼續發揮基礎性作用。同時，緩釋對症藥物在長期症狀調節方面佔據獨特的地位，而黏彈性補充劑則在關節內給藥領域佔據著特定的細分市場，為尋求局部動態支持的患者提供服務。給藥途徑影響臨床定位和應用趨勢；注射劑分為關節內給藥（用於標靶關節治療的首選）和肌肉注射（用於特定治療路徑）。口服劑分為膠囊、液體和片劑，以滿足患者的用藥依從性和劑量需求，而外用療法則以乳膏、凝膠和貼劑的形式提供，以滿足優先考慮安全性或合併其他疾病的患者群體的需求。

區域戰略資訊解釋了美洲、歐洲、中東和非洲以及亞太地區的趨勢如何決定市場准入、採用和製造優先事項。

區域趨勢正以顯著不同的方式影響臨床應用、監管方法和供應鏈設計。在美洲，醫療保健系統和私人保險公司專注於成本效益和永續的功能性獲益的證據，這加速了人們對能夠顯著改善患者活動能力並減少急診資源使用的治療方法的興趣。北美強大的生產能力和成熟的專科醫療保健基礎設施支持先進注射劑和聯合療法方案的快速推廣，但採購流程日益嚴格的審查也提高了人們對透明供應保障的期望。

雇主層面的洞察，展示如何利用產品創新、夥伴關係和製造韌性來確保商業性和臨床差異化。

骨關節炎疼痛管理領域的主要企業正採取多元化但又互補的策略，以保持競爭力並實現臨床差異化。許多公司正在投資研發新一代製劑，以提高藥物對關節的標靶暴露量，同時降低全身暴露量，進而改善老年患者和合併其他疾病患者的耐受性。生物技術開發商、專科藥房和分銷合作夥伴之間的策略合作正被充分利用，以加速產品進入市場，提高患者用藥依從性，並建立長期的患者支援服務，收集真實世界的療效數據。

從支付方的觀點，為製造商和相關人員提供切實可行的建議，以加強骨關節炎治療的供應韌性、臨床意義和價值證明。

產業領導者應採取多管齊下的策略，以保持發展勢頭並應對短期挑戰，同時建立長期競爭優勢。首先，他們應優先考慮供應商多元化，並投資於本地灌裝、包裝和無菌生產能力，以降低跨境貿易波動風險，並滿足醫院對供應韌性的採購要求。其次，產品開發應與實際臨床需求相契合，重點在於能夠提高老年人用藥安全性、便於門診給藥以及減輕居家看護者負擔的劑型。第三，他們應加快累積將藥物療效、功能性結果和醫療資源可用性聯繫起來的真實世界證據，從而支持與支付方的對話以及基於結果的合約。

本文清楚地闡述了一種混合方法研究方法，整合了主要臨床發現、次要資訊和基於情境的分析，從而確保了嚴謹而實用的見解。

本研究採用混合方法，結合與關鍵相關人員的對話、有針對性的二手資訊收集和定量分析，以得出可靠且可操作的結論。主要研究包括對執業風濕症醫師、骨科醫生、支付方、醫院採購經理和製藥公司高管進行結構化訪談，以了解治療偏好、處方集趨勢和採購因素。二手資訊收集自同行評審的臨床文獻、監管出版刊物、公開的臨床試驗註冊資訊、專利申請和檢驗的供應鏈資料庫，從而對治療趨勢、研發管線活動和製造地分佈進行多方面分析。

對相關人員在不斷發展的骨關節炎治療領域取得成功必須整合的臨床、商業性和營運要求進行權威的綜合分析。

總之，骨關節炎鎮痛藥市場正受到臨床創新、分銷管道演變和供應鏈需求的重塑，這些因素共同定義了新的商業性和臨床成功標準。有效的策略取決於透過標靶製劑和給藥機制提供差異化的臨床價值，同時展現對保險公司和臨床醫生至關重要的實際功能性獲益。以區域生產安排和透明採購慣例為基礎的供應韌性是商業性信譽的關鍵要素。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：骨關節炎止痛藥市場：依產品類型分類

  • 皮質類固醇
  • Cyclooxygenase2抑制劑
  • 非類固醇消炎劑
  • 症狀治療及緩釋藥物
  • 黏彈性補充劑

第9章：骨關節炎鎮痛藥市場：依給藥途徑分類

  • 注射藥物
    • 關節內
    • 肌肉內部
  • 口服
    • 膠囊
    • 液體
    • 藥片
  • 外用
    • 奶油
    • 凝膠
    • 修補

第10章：依患者年齡層分類的骨關節炎鎮痛藥市場

  • 18歲以下的青少年
  • 18-64歲的成年人
  • 65歲及以上的老年人

第11章 骨關節炎鎮痛藥市場：依疾病嚴重程度分類

  • 溫和的
  • 緩和
  • 嚴重

第12章 骨關節炎鎮痛藥市場：依最終用戶分類

  • 診所
  • 家庭醫療保健
  • 醫院

第13章：骨關節炎鎮痛藥市場：依通路分類

  • 離線
  • 線上

第14章：骨關節炎止痛藥市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：骨關節炎止痛藥市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 骨關節炎止痛藥市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國骨關節炎止痛藥市場

第18章：中國骨關節炎止痛藥市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Bayer AG
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis AG
  • Perrigo Company plc
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-0376B2CAAFEB

The Osteoarthritis Pain Drug Market was valued at USD 9.45 billion in 2025 and is projected to grow to USD 10.31 billion in 2026, with a CAGR of 9.62%, reaching USD 17.99 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.45 billion
Estimated Year [2026] USD 10.31 billion
Forecast Year [2032] USD 17.99 billion
CAGR (%) 9.62%

A strategic introduction to the evolving osteoarthritis pain drug environment that frames clinical imperatives, patient diversity, and practical innovation pathways for stakeholders

Osteoarthritis remains a complex clinical challenge driven by heterogeneous patient needs, chronic pain trajectories, and variable functional impacts across age groups and disease severity. Clinicians and payers increasingly seek therapies that balance rapid symptom relief, safety for long-term use, and demonstrable effects on mobility and quality of life. Recent clinical innovation has focused on refining existing pharmacologic classes and exploring novel mechanisms to address persistent gaps in durable pain control and disease progression.

Against this backdrop, manufacturers are adapting development priorities to emphasize differentiated delivery formats, improved safety profiles for older adults, and solutions compatible with ambulatory and home-based care models. Concurrently, health systems and specialty clinics are demanding evidence that links product performance to real-world functional outcomes. This introduction sets the stage for a detailed examination of therapeutic classes, route-of-administration trends, distribution dynamics, and patient segmentation that together shape the commercial and clinical contours of the osteoarthritis pain drug space.

Transformative scientific, clinical, and commercial shifts reshaping therapeutic choices, delivery formats, and evidence expectations across the osteoarthritis pain landscape

The osteoarthritis drug landscape is undergoing transformative shifts driven by scientific advances, shifting payer expectations, and technology-enabled care models. Biologic approaches and targeted small molecules are redefining therapeutic possibilities, while formulation science continues to deliver options that improve tolerability and adherence. At the same time, the emergence of digital health platforms and remote monitoring is enabling more precise assessment of pain trajectories and functional improvement, which in turn supports outcomes-based contracting and personalized treatment algorithms.

Commercially, manufacturers are responding to these shifts through strategic alliances, specialty partnerships, and differentiated go-to-market strategies that prioritize high-value clinical niches. As regulatory pathways adapt to accommodate real-world evidence and accelerated approvals, the ability to generate robust post-authorization data will determine which candidates achieve sustainable uptake. In addition, ongoing improvements in sterile injectable manufacturing and advanced topical formulations are changing how clinicians select therapies across care settings, from clinics to home-based care, which reinforces the importance of aligning development with practical delivery constraints.

An analytical view of how tariff developments through 2025 have reshaped supply chains, manufacturing footprints, and procurement priorities across osteoarthritis therapeutics

The cumulative trade measures and tariff policy shifts introduced through 2025 have imparted a multifaceted impact on supply chains, manufacturing economics, and procurement strategies for osteoarthritis therapeutics. Increased duties on key intermediates and finished imports have elevated input cost volatility for companies reliant on cross-border API and excipient flows. As a direct consequence, manufacturers and contract development and manufacturing organizations have accelerated supplier diversification, expanded local fill-finish capacity, and reevaluated long-term sourcing agreements to mitigate exposure to tariff-driven cost escalation.

Beyond cost considerations, tariffs have influenced strategic decisions around where to locate high-volume sterile manufacturing versus specialized formulation work. Injectable therapies, which require stringent sterile processes and validated cold-chain logistics, have seen heightened attention to domestic or regionally proximate production to reduce cross-border complexity. Conversely, topical and oral formulations with longer shelf stability have provided more flexibility to absorb tariff-related logistics changes through inventory management and selective sourcing. Payers and hospital procurement teams have responded by intensifying scrutiny of total landed cost and supply resilience, prompting manufacturers to present more transparent supply chain assurances and contingency plans. In sum, tariff dynamics through 2025 have reinforced resilience as a core commercial differentiator, compelling companies to align manufacturing footprint, procurement strategies, and pricing models with evolving trade realities.

Actionable segmentation insights revealing how product types, administration routes, channel dynamics, and patient cohorts systematically determine clinical positioning and commercial strategy

A segmentation-led understanding of the osteoarthritis therapeutic ecosystem reveals distinct clinical and commercial behaviors that inform product strategy across therapeutic classes and delivery routes. In terms of product type, corticosteroids continue to be relied upon for acute flare management while cyclooxygenase 2 inhibitors and nonsteroidal anti-inflammatory drugs remain foundational for systemic symptom control, symptomatic slow-acting drugs serve niche roles in long-term symptom modulation, and viscosupplements occupy a specific intra-articular niche for patients seeking localized biomechanical support. Route of administration shapes clinical positioning and adoption dynamics, with injectable approaches subdividing into intra-articular options favored for targeted joint therapy and intramuscular formats used in specific care pathways, oral administration dividing into capsules, liquid formulations, and tablets to match adherence and dosing needs, and topical therapies offered as creams, gels, and patches that cater to safety-conscious or comorbid populations.

Distribution channel choices reflect purchasing behavior and care setting needs, balancing hospital pharmacy procurement for acute procedural use with retail pharmacy access for chronic management and growing online pharmacy channels that facilitate direct-to-patient fulfillment and adherence programs. End-user segmentation shows distinct expectations across clinics that favor rapid-onset, procedure-compatible options; home healthcare that prioritizes ease-of-use and safety for extended treatment; and hospitals that emphasize efficacy in severe presentations and supply reliability. Age-based considerations-adolescents under 18, adults 18 to 64, and elderly 65 plus-drive formulation and dosing priorities, with the elderly cohort demanding heightened attention to comorbidity interactions and polypharmacy. Finally, disease severity bands of mild, moderate, and severe map directly to therapeutic intensity and delivery format, where milder presentations trend toward topical and oral maintenance therapies and more severe disease necessitates injectable or combined modality strategies. Together, these segmentation dimensions provide a multidimensional framework to prioritize development investments, label positioning, and market access tactics.

Regional strategic intelligence describing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics determine access, adoption, and manufacturing priorities

Regional dynamics are influencing clinical adoption, regulatory approaches, and supply chain design in markedly different ways across major geographies. In the Americas, health systems and private payers are focusing on cost-effectiveness and evidence of durable functional benefit, which accelerates interest in therapies that can demonstrate measurable improvements in mobility and reduced utilization of acute care resources. North American manufacturing capacity and a mature specialty care infrastructure support rapid adoption of advanced injectables and combination treatment protocols, while procurement scrutiny drives expectations for transparent supply assurances.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse reimbursement mechanisms require targeted market access strategies that align clinical value propositions with local HTA frameworks and payer priorities. The EMEA region also presents significant opportunities to align public health initiatives with aging populations in certain markets, creating demand for safer chronic-use therapies and community-delivered care models. In the Asia-Pacific region, demographic shifts, rapid expansion of specialty clinics, and an agile contract manufacturing sector are fostering faster uptake of novel formulations, although fragmented reimbursement and variable access remain constraints. Across regions, interoperability of real-world data and regional manufacturing investments continue to be decisive factors shaping where companies prioritize launches and scale production lines.

Corporate-level insights showing how product innovation, partnerships, and manufacturing resilience are being deployed to secure commercial and clinical differentiation

Leading companies in the osteoarthritis pain space are pursuing distinct but complementary strategies to preserve competitiveness and capture clinical differentiation. Many are investing in next-generation formulations that reduce systemic exposure while enhancing targeted exposure at the joint, thereby improving tolerability for older adults and patients with comorbidities. Strategic alliances across biotech developers, specialty pharmacies, and distribution partners are being used to accelerate market entry and to build longitudinal patient support services that enhance adherence and gather real-world outcomes data.

On the operational front, firms are strengthening sterile manufacturing capabilities and pursuing geographic diversification to reduce supply chain risk and better align with regional procurement trends. Commercially, there is a growing emphasis on value demonstration through health economic modeling and targeted outcomes studies designed to speak to institutional buyers and payers. Firms that combine clinical differentiation with transparent supply chain credentials and a clear pathway to demonstrate real-world impact are establishing clearer routes to premium positioning within clinical formularies and specialist prescribing environments.

Actionable recommendations for manufacturers and stakeholders to enhance supply resilience, clinical relevance, and payer-aligned value demonstration in osteoarthritis therapeutics

Industry leaders should adopt a multifaceted approach to sustain momentum and address near-term disruptions while building long-term competitive advantage. First, prioritize supplier diversification and invest in regional fill-finish and sterile production capacity to reduce exposure to cross-border trade volatility and to meet hospital procurement expectations for supply resilience. Second, align product development with pragmatic clinical needs by focusing on formulations that improve safety for older adults, enable outpatient administration, and reduce caregiver burden in home healthcare settings. Third, accelerate generation of real-world evidence that links drug performance to functional outcomes and health resource utilization to support payer conversations and outcomes-based contracts.

Further, companies should expand digital engagement and patient support infrastructure to improve adherence and to capture continuous outcomes data that can inform iterative product improvements. Commercial strategies should include targeted channel optimization to balance hospital pharmacy penetration with retail and online pharmacy access, ensuring that distribution meets both acute procedural demand and chronic maintenance needs. Finally, embed scenario planning into procurement and pricing strategies so that tariff changes, supply disruptions, or reimbursement shifts can be accommodated without compromising clinical supply or strategic launch timelines.

Clear explanation of the mixed-methods research approach integrating primary clinical insights, secondary intelligence, and scenario-based analysis to ensure rigorous and actionable findings

This research applied a mixed-methods approach combining primary stakeholder engagement, targeted secondary intelligence, and quantitative synthesis to ensure robust and actionable conclusions. Primary research included structured interviews with practicing rheumatologists, orthopedic surgeons, payers, hospital procurement leads, and senior commercial executives to capture therapeutic preferences, formulary dynamics, and procurement drivers. Secondary inputs were drawn from peer-reviewed clinical literature, regulatory publications, public clinical trial registries, patent filings, and validated supply chain databases to triangulate therapeutic trends, pipeline activity, and manufacturing footprints.

Analytic methods incorporated segmentation mapping, scenario analysis to explore supply disruption and tariff impacts, and cross-validation techniques to reconcile qualitative inputs with observed procurement behaviors. Quality assurance included expert review panels and methodological audits to confirm consistency of thematic findings. Together, these approaches produced a defensible evidence base that links clinical needs, distribution realities, and commercial imperatives to practical recommendations for product development and market access.

Conclusive synthesis of clinical, commercial, and operational imperatives that stakeholders must integrate to succeed in the evolving osteoarthritis therapeutic arena

In conclusion, the osteoarthritis pain drug environment is being reshaped by clinical innovation, distribution evolution, and supply chain imperatives that together define new commercial and clinical thresholds for success. Effective strategies will hinge on delivering differentiated clinical value through targeted formulations and delivery mechanisms, while simultaneously demonstrating real-world functional benefits that matter to payers and clinicians. Supply resilience, evidenced by regional manufacturing and transparent procurement practices, has become a nonnegotiable element of commercial credibility.

Stakeholders who align development portfolios with patient-centric outcomes, invest in evidence generation, and adopt flexible manufacturing and distribution models will be best positioned to navigate the evolving landscape. By integrating these strategic priorities into development and commercialization plans, organizations can better meet the diverse needs of clinicians and patients while maintaining operational agility in a dynamic regulatory and trade environment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Osteoarthritis Pain Drug Market, by Product Type

  • 8.1. Corticosteroids
  • 8.2. Cyclooxygenase 2 Inhibitors
  • 8.3. Nonsteroidal Anti-Inflammatory Drugs
  • 8.4. Symptomatic Slow Acting Drugs
  • 8.5. Viscosupplements

9. Osteoarthritis Pain Drug Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intra Articular
    • 9.1.2. Intramuscular
  • 9.2. Oral
    • 9.2.1. Capsules
    • 9.2.2. Liquid
    • 9.2.3. Tablets
  • 9.3. Topical
    • 9.3.1. Cream
    • 9.3.2. Gel
    • 9.3.3. Patch

10. Osteoarthritis Pain Drug Market, by Patient Age Group

  • 10.1. Adolescents Under 18
  • 10.2. Adults 18 64
  • 10.3. Elderly 65+

11. Osteoarthritis Pain Drug Market, by Disease Severity

  • 11.1. Mild
  • 11.2. Moderate
  • 11.3. Severe

12. Osteoarthritis Pain Drug Market, by End User

  • 12.1. Clinics
  • 12.2. Home Healthcare
  • 12.3. Hospitals

13. Osteoarthritis Pain Drug Market, by Distribution Channel

  • 13.1. Offline
  • 13.2. Online

14. Osteoarthritis Pain Drug Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Osteoarthritis Pain Drug Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Osteoarthritis Pain Drug Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Osteoarthritis Pain Drug Market

18. China Osteoarthritis Pain Drug Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Bayer AG
  • 19.7. GlaxoSmithKline plc
  • 19.8. Johnson & Johnson
  • 19.9. Merck & Co., Inc.
  • 19.10. Novartis AG
  • 19.11. Perrigo Company plc
  • 19.12. Pfizer Inc.
  • 19.13. Sandoz International GmbH
  • 19.14. Sanofi S.A.
  • 19.15. Teva Pharmaceutical Industries Ltd.
  • 19.16. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CYCLOOXYGENASE 2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SYMPTOMATIC SLOW ACTING DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY VISCOSUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRA ARTICULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADOLESCENTS UNDER 18, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ADULTS 18 64, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ELDERLY 65+, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 185. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 188. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 189. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 190. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 191. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 193. GCC OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 220. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 221. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 222. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 223. G7 OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 224. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 228. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 229. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 232. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 233. NATO OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA OSTEOARTHRITIS PAIN DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)